⌘K
Loading ticker…
As of 2026-08-24, SELLAS Life Sciences Group, Inc. Common Stock (SLS) has a 3-month relative strength percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 99. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.0%, relative volume 1.35×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
SLS is in a stage 2 uptrend, week 4. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 21.1% / 129.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
SLS is held by 15 ETFs as of May 2026. Top owner: VTWO at 0.05% weight, $8M notional. Top 3 carry $16M.
Held by 27 ETFs · $97M across latest filings · largest weight 1.83% (COPA).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| new |
| CANC | 0.22% | $379K | new |
| AVDE | 0.00% | $338K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $131K | — |
| ITWO | 0.04% | $75K | +0.02 pp |
Showing 10 of 15 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SLS Jan avg: 14.21% median: 20.34% win: 50% σ: 42.93% n: 4 2022-04-12 → 2026-07-31 | SLS Feb avg: 3.08% median: 1.80% win: 50% σ: 49.66% n: 4 2022-04-12 → 2026-07-31 | SLS Mar avg: -9.51% median: -11.34% win: 0% σ: 7.02% n: 4 2022-04-12 → 2026-07-31 | SLS Apr avg: 11.95% median: 17.02% win: 60% σ: 24.84% n: 5 2022-04-12 → 2026-07-31 | SLS May avg: 29.26% median: 13.71% win: 100% σ: 33.19% n: 5 2022-04-12 → 2026-07-31 | SLS Jun avg: 7.13% median: -8.46% win: 40% σ: 35.35% n: 5 2022-04-12 → 2026-07-31 | SLS Jul avg: -8.57% median: -2.52% win: 40% σ: 20.40% n: 5 2022-04-12 → 2026-07-31 | SLS Aug avg: 10.28% median: 15.37% win: 75% σ: 14.40% n: 4 2022-04-12 → 2026-07-31 (current) | SLS Sep avg: -10.42% median: -9.62% win: 25% σ: 19.37% n: 4 2022-04-12 → 2026-07-31 | SLS Oct avg: 24.57% median: 3.72% win: 50% σ: 74.82% n: 4 2022-04-12 → 2026-07-31 | SLS Nov avg: -14.24% median: -7.61% win: 25% σ: 24.32% n: 4 2022-04-12 → 2026-07-31 | SLS Dec avg: 31.36% median: 0.33% win: 50% σ: 67.70% n: 4 2022-04-12 → 2026-07-31 |